1.5 billion bioreactor industrialization project settled in Wuxi

Recently, the "Human lactoferrin dairy cow bioreactor industrialization project", led by the team of academician Li Ning of the Chinese Academy of Engineering, was launched in Wuxi New District, Jiangsu Province. It is reported that the project has achieved the integration of bio-pharmaceuticals and bio-agriculture with a registered capital of 275 million yuan, a total investment of 1.5 billion yuan, and an estimated annual sales of 15 billion yuan after full production.

It is understood that animal bioreactors represented by cow bioreactors are biopharmaceutical technologies that produce medicinal and health care proteins in animal mammary glands through genetic engineering techniques. Compared with microbial fermentation and mammalian cell culture, animal bioreactors have high efficiency. It is the most advanced biopharmaceutical technology in the world with its advantages of low cost, low investment, large scale, and low carbon and environmental protection. Human lactoferrin is an important functional ingredient in human breast milk. It has a broad-spectrum antibacterial and bone-enhancing function and can develop a series of major health products. It has broad market prospects. Currently, many pharmaceutical companies in the world compete for development. Lactoferrin pharmaceutical products. As a leader in the research and development of animal bioreactors and protein drugs in China, the human lactoferrin dairy cow bioreactor project led by Academician Li Ning has achieved more than 10 national invention patents and has been in the national “Eleventh Five-Year” major scientific and technological achievements exhibition. It was listed as a major landmark achievement. Academician Li Ning’s current team has completed preclinical studies and small-scale pilot production of Rutie Weikang capsules, bio-blood oral liquids, anti-small cell lung cancer oral medicines and other products. According to relevant experts of the Chinese Academy of Agricultural Sciences, the market value of human lactoferrin dairy cow bioreactor related products will exceed 40 billion yuan.